Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer
- First Online:
- Cite this article as:
- Dost, R.J., Glaudemans, A.W.J.M., Breeuwsma, A.J. et al. Eur J Nucl Med Mol Imaging (2013) 40(Suppl 1): 41. doi:10.1007/s00259-013-2398-7
Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy. To stage the cancer, choline positron emission tomography (PET)/CT can be performed. It is generally thought that androgen deprivation therapy does not influence choline PET/CT. In this article we focus on the molecular backgrounds of choline and androgens, and the results of preclinical and clinical studies performed using PET/CT.
Using PubMed, we looked for the relevant articles about androgen deprivation therapy and choline PET/CT.
During ADT, a tendency of decreased uptake of choline in prostate cancer was observed, in particular in hormone-naïve patients.
We conclude that in order to prevent false-negative choline PET/CT scans androgen deprivation should be withheld prior to scanning, especially in hormone-naïve patients.